المؤلفون: Pickering, Chad, Aiyetan, Paul, Gege Xu, Mitchell, Alan, Rice, Rachel, Najjar, Yana G., Markowitz, Joseph, Ebert, Lisa M., Brown, Michael P., Tapia-Rico, Gonzalo, Frederick, Dennie, Xin Cong, Serie, Daniel, Lindpaintner, Klaus, Schwarz, Flavio, Boland, Genevieve M.

المصدر: Frontiers in Immunology; 2023, p1-14, 14p

مصطلحات موضوعية: IMMUNE checkpoint inhibitors, IPILIMUMAB, ARTIFICIAL intelligence, MELANOMA, BIOMARKERS, METASTASIS, TURNAROUND time

المؤلفون: Shaikh, Saba S., Yan Zang, Hanmer, Janel, Hong Wang, Yan Lin, Davar, Diwakar, Zarour, Hassane M., Kirkwood, John M., Najjar, Yana G.

المصدر: Frontiers in Oncology; 11/23/2022, Vol. 12, p01-07, 7p

مصطلحات موضوعية: VEMURAFENIB, INFORMED consent (Medical law), DACARBAZINE, PEMBROLIZUMAB, IPILIMUMAB, MELANOMA, BLOOD flow

المؤلفون: Najjar, Yana G.¹, Fei Ding², Yan Lin², VanderWeele, Robert¹, Butterfield, Lisa H.³, Tarhini, Ahmad A.⁴ tarhiniaa@upmc.edu, Ding, Fei² (AUTHOR), Lin, Yan² (AUTHOR)

المصدر: Journal of Translational Medicine. 2/21/2017, Vol. 15, p1-9. 9p.

مصطلحات موضوعية: *MELANOMA treatment, *IPILIMUMAB, *T cells, *CYTOKINES, *ADJUVANT treatment of cancer, *PROGRESSION-free survival, *THERAPEUTICS

المؤلفون: Najjar, Yana G., Kirkwood, John M.

المصدر: American Journal of Hematology/Oncology; Nov2014, Vol. 10 Issue 5, p17-19, 3p

مصطلحات موضوعية: THERAPEUTIC use of monoclonal antibodies, ENZYME inhibitors, MELANOMA, METASTASIS, MONOCLONAL antibodies, DRUG approval, DISEASE progression, IPILIMUMAB

الشركة/الكيان: UNITED States. Food & Drug Administration